NeuroMetrix Inc (NURO)

1.64
0.06 3.50
NASDAQ : Health Care
Prev Close 1.70
Open 1.66
Day Low/High 1.60 / 1.72
52 Wk Low/High 1.35 / 4.96
Volume 74.94K
Avg Volume 73.40K
Exchange NASDAQ
Shares Outstanding 4.39M
Market Cap 7.55M
EPS -7.80
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

NeuroMetrix Expands DPNCheck Commercialization In Mexico

NeuroMetrix Expands DPNCheck Commercialization In Mexico

NeuroMetrix, Inc. ( NURO) today reported commercial expansion of DPNCheck ® in Mexico following receipt of a purchase order from one of Mexico's six major government healthcare institutions.

NeuroMetrix' Quell Device Makes Second Appearance At The American Podiatric Medical Association Annual Scientific Meeting

NeuroMetrix' Quell Device Makes Second Appearance At The American Podiatric Medical Association Annual Scientific Meeting

NeuroMetrix, Inc. (NASDAQ:NURO) today announced that Quell ® Wearable Pain Relief Technology ™ will be featured for the second year in a row at the American Podiatric Medical Association's Annual Scientific...

NeuroMetrix Announces Launch Of Quell Sport Electrode

NeuroMetrix Announces Launch Of Quell Sport Electrode

NeuroMetrix, Inc. (Nasdaq: NURO) today announced commercial launch of a new Sport Electrode for its innovative Quell ® Wearable Pain Relief Technology™.

NeuroMetrix Reports Peer-Reviewed Publication Of Initial Quell Study

NeuroMetrix Reports Peer-Reviewed Publication Of Initial Quell Study

NeuroMetrix, Inc. (Nasdaq: NURO), today reported publication of the initial Quell ® study in the Journal of Pain Research.

NeuroMetrix Announces Quell Distribution Agreement With WBC Group

NeuroMetrix Announces Quell Distribution Agreement With WBC Group

NeuroMetrix, Inc. (Nasdaq: NURO) announced today that WBC Group, LLC will be the exclusive distributor of Quell ® Wearable Pain Relief Technology ™ to chiropractors, physical therapists, physical fitness...

NeuroMetrix To Sponsor Clinical Study At The Scripps Translational Science Institute Assessing The Impact Of Quell Technology On Opioid Use And Pain In Cancer Patients

NeuroMetrix To Sponsor Clinical Study At The Scripps Translational Science Institute Assessing The Impact Of Quell Technology On Opioid Use And Pain In Cancer Patients

NeuroMetrix, Inc. (Nasdaq: NURO) and the Scripps Translational Science Institute (STSI) today announced a clinical study of Quell ® wearable pain relief technology in patients with cancer related pain.

NeuroMetrix Submits CE Mark Application For Quell Wearable Pain Relief Device

NeuroMetrix Submits CE Mark Application For Quell Wearable Pain Relief Device

NeuroMetrix, Inc. (Nasdaq: NURO) announced today that a CE (Conformité Européenne ) Technical File Application for Quell ® has been submitted to TUV SUD Product Service GmbH, which is one of the...

NeuroMetrix Showcases Quell Technology At The Western Foot & Ankle Conference

NeuroMetrix Showcases Quell Technology At The Western Foot & Ankle Conference

NeuroMetrix, Inc. (NASDAQ:NURO) today announced that Quell ® Wearable Pain Relief Technology™ will be featured at the Western Foot & Ankle Conference to be held June 23-26 in Anaheim, CA.

NeuroMetrix Announces Quell Distribution In Canada

NeuroMetrix Announces Quell Distribution In Canada

 NeuroMetrix, Inc. (Nasdaq: NURO) announced today that Quell ® Wearable Pain Relief Technology ™ is available in Canada via Amazon Canada.

NeuroMetrix Reports Executive Stock Transactions During May 2016

NeuroMetrix Reports Executive Stock Transactions During May 2016

NeuroMetrix, Inc. (Nasdaq: NURO) which developed and markets Quell ® Wearable Pain Relief Technology ™, reported purchases during May 2016 of the company's common stock by its Chief Executive Officer, Dr.

NeuroMetrix Showcases Quell Technology At SLEEP 2016, The 30th Anniversary Meeting Of The Associated Professional Sleep Societies

NeuroMetrix Showcases Quell Technology At SLEEP 2016, The 30th Anniversary Meeting Of The Associated Professional Sleep Societies

NeuroMetrix, Inc. (NASDAQ:NURO) today announced that Quell ® Wearable Pain Relief Technology ™ will be featured at SLEEP 2016, which is a joint meeting of the American Academy of Sleep Medicine and the...

NeuroMetrix Closes $21.3 Million At-The-Market Private Placement Of Preferred Stock And Warrants And Redeems $13.8 Million Of Outstanding Preferred Stock

NeuroMetrix Closes $21.3 Million At-The-Market Private Placement Of Preferred Stock And Warrants And Redeems $13.8 Million Of Outstanding Preferred Stock

NeuroMetrix, Inc. (Nasdaq: NURO) reported that it has closed its previously announced private placement of preferred stock and warrants.

NeuroMetrix Celebrates 20 Year Anniversary

NeuroMetrix Celebrates 20 Year Anniversary

NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it is celebrating its twenty year anniversary.

NeuroMetrix Announces $21.3 Million At The Market Private Placement Of Preferred Stock And Warrants

NeuroMetrix Announces $21.3 Million At The Market Private Placement Of Preferred Stock And Warrants

NeuroMetrix, Inc. (NASDAQ: NURO) announced today that it entered into a definitive securities purchase agreement with a healthcare dedicated institutional investor in connection with a private placement of 21,300 shares of...

NeuroMetrix Announces Availability Of Quell In Approximately 1,000 Chain Drug Stores

NeuroMetrix Announces Availability Of Quell In Approximately 1,000 Chain Drug Stores

NeuroMetrix, Inc. (Nasdaq: NURO) announced today that Quell ® will be available, beginning in June 2016, in approximately 1,000 chain drug stores as part of a retail test with the two largest US drug retailers.

NeuroMetrix To Present At The LD Micro Invitational Conference On June 7, 2016

NeuroMetrix To Present At The LD Micro Invitational Conference On June 7, 2016

NeuroMetrix, Inc. (NASDAQ:NURO) today announced that Shai N.

NeuroMetrix Reports The Launch Of The Quell® Health Cloud For Android

NeuroMetrix Reports The Launch Of The Quell® Health Cloud For Android

NeuroMetrix, Inc. (Nasdaq: NURO), announced today the launch of the Quell Health Cloud for Android The updated Android app allows consumers to set up accounts on the Quell Health Cloud where their data is automatically...

NeuroMetrix Announces Frank McGillin, SVP And General Manager, Consumer To Participate In A Digital Health Summer Summit Panel At BIO 2016

NeuroMetrix Announces Frank McGillin, SVP And General Manager, Consumer To Participate In A Digital Health Summer Summit Panel At BIO 2016

NeuroMetrix, Inc. (Nasdaq: NURO) announced that Frank McGillin, Senior Vice President and General Manager, Consumer will participate in a panel discussion entitled "The Rise of Enterprise & Condition-Specific Wearables"...

NeuroMetrix Announces Availability Of Quell At Brookstone.com

NeuroMetrix Announces Availability Of Quell At Brookstone.com

NeuroMetrix, Inc. (Nasdaq:NURO) announced today that Quell ® is now available at Brookstone.

NeuroMetrix Announces Launch Of National TV Campaign To Support Quell

NeuroMetrix Announces Launch Of National TV Campaign To Support Quell

NeuroMetrix, Inc. (Nasdaq: NURO) has launched national television advertising to promote the company's innovative Quell ® Wearable Pain Relief Technology™.

NeuroMetrix To Present At First Look Equities Summit

NeuroMetrix To Present At First Look Equities Summit

NeuroMetrix, Inc. (NASDAQ:NURO) announced today that Shai N.

NeuroMetrix Reports Q1 2016 Financial Results And Highlights

NeuroMetrix Reports Q1 2016 Financial Results And Highlights

NeuroMetrix, Inc. (Nasdaq: NURO), today reported financial and business highlights for the quarter ended March 31, 2016.

NeuroMetrix, Inc. Announces Date For 2016 First Quarter Financial Results Conference Call

NeuroMetrix, Inc. Announces Date For 2016 First Quarter Financial Results Conference Call

NeuroMetrix, Inc. (NASDAQ: NURO) announced today that it plans to issue its 2016 first quarter financial results before the opening of the market on April 21, 2016.

NeuroMetrix Reports High Level Of Media Coverage For Quell In First Quarter

NeuroMetrix Reports High Level Of Media Coverage For Quell In First Quarter

NeuroMetrix, Inc. (NASDAQ:NURO) today reported continued strong media attention focusing on the company's innovative Quell ® Wearable Pain Relief Technology ™.

NeuroMetrix Announces Collaboration With Premera Blue Cross To Pilot Quell Wearable Pain Relief Technology

NeuroMetrix Announces Collaboration With Premera Blue Cross To Pilot Quell Wearable Pain Relief Technology

NeuroMetrix, Inc. (Nasdaq: NURO) announced today that Premera Blue Cross, a leading health plan in the Pacific Northwest, will pilot the Quell ® Wearable Pain Relief device within their organization.

NeuroMetrix To Present At 2016 Sidoti Emerging Growth Convention

NeuroMetrix To Present At 2016 Sidoti Emerging Growth Convention

NeuroMetrix, Inc. (NASDAQ:NURO) announced today that Shai N.

NeuroMetrix Showcases Quell Technology At The Midwest Podiatry Conference

NeuroMetrix Showcases Quell Technology At The Midwest Podiatry Conference

NeuroMetrix, Inc. (NASDAQ:NURO) today announced that Quell® Wearable Pain Relief Technology ™ will be featured at the Midwest Podiatry Conference to be held March 31-April 3 at the Hyatt Regency Chicago.

NeuroMetrix Announces Availability Of Quell At Target

NeuroMetrix Announces Availability Of Quell At Target

NeuroMetrix, Inc. (Nasdaq: NURO) announced today that Quell ® will be included in a new digital health initiative in over 500 Target ® stores nationwide beginning in April.